Interface Biologics

Endexo technology encompasses a range of low molecular weight additives for reduced thrombus formation on devices without the use of heparin. It works with a wide range of polymers with a variety of hardnesses, temperatures and processing means. Read more



Source: Interface Biologics Inc (IBI).

AngioDynamics and Interface Biologics Inc (IBI) have extended the licensing agreement for Endexo anti-thrombogenic polymer to include central venous catheters in addition to peripherally inserted catheters (PICCs), ports and dialysis catheters. Read more